Ntellas, P., Park, H., Culm, K., Lee, J., Youssoufian, H., Mockbee, C., . . . Chau, I. (2026). Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes. Current Oncology, 33(6), 319. https://doi.org/10.3390/curroncol33060319
Chicago Style (17th ed.) CitationNtellas, Panagiotis, Haeseong Park, Kerry Culm, Jeeyun Lee, Hagop Youssoufian, Colleen Mockbee, Mark Uhlik, Laura Benjamin, and Ian Chau. "Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes." Current Oncology 33, no. 6 (2026): 319. https://doi.org/10.3390/curroncol33060319.
MLA (9th ed.) CitationNtellas, Panagiotis, et al. "Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes." Current Oncology, vol. 33, no. 6, 2026, p. 319, https://doi.org/10.3390/curroncol33060319.
